Psoriasis

LATEST NEWS

Biologic Agent Use Associated With Lower Hospitalization Risk for Patients With Psoriasis and COVID-19

By

Brandon May

The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study.

RediTrex Now Available for RA, pJIA, Psoriasis Treatment

By

Diana Ernst, RPh

RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.

Treatment of Psoriasis With IBD May Require Higher Doses of Risankizumab

By

Rose Reeb

A case report of a man with plaque psoriasis and comorbidities that include psoriatic arthritis and ulcerative colitis.

Risankizumab After Guselkumab Failure as Effective as Risankizumab Alone

By

Rose Reeb

A novel study investigates an in-class IL-23 inhibitor switch from guselkumab to risankizumab for patients with psoriasis.

Ustekinumab Efficacious for Children With Moderate to Severe Psoriasis

By

Emily Pond

Early efforts to characterize the efficacy of treatment of psoriasis with ustekinumab in pediatric patients are reviewed.

Psoriasis Treatment and VCAM-1, E-Selectin Levels May Affect Risk for Cardiovascular Disease

By

Colby Stong

VCAM-1 and E-selectin levels and their relationship with psoriasis severity were evaluated.

Synovitis Reduction Observed With Secukinumab in Psoriatic Arthritis Trial

By

Brian Park, PharmD

The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.

Body Image Has Key Role in Psoriasis Severity Perception, Acceptance, and Disability

By

Colby Stong

Clinical and positive psychological variables that contribute significantly to psoriasis disability were identified.

Psoriasis Is Associated With Impaired Coronary Blood Flow

By

Colby Stong

PASI score association with abnormal physiology as defined by low V/M independent of non-calcified coronary burden was investigated.

Deucravacitinib Shows Superiority to Apremilast in Psoriasis Trial

By

Brian Park, PharmD

A phase 3 trial evaluating the efficacy and safety of deucravacitinib (BMS-986165; Bristol Myers Squibb), a novel, oral, selective TYK2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis met both co-primary and secondary end points.